You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Chemotherapy in Pregnancy

BREWER, MOLLY DVM, MD, MS*; KUECK, ANGELA MD*; RUNOWICZ, CAROLYN D. MD*,†

Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e318236e9f9
Cancer In Pregnancy
Abstract

One in 1000 pregnancies is complicated with cancer with the most common tumors being breast cancer, cervical cancer, thyroid, leukemia, lymphoma, and ovarian cancer. It is often assumed that cancer during pregnancy necessitates sacrificing the well-being of the fetus but in most cases appropriate treatment can be offered to the mother without placing the fetus at serious risk. The care of a pregnant woman with cancer involves evaluation of competing maternal and fetal risks and benefits. Although it is rare to administer chemotherapy during pregnancy, the risks depend on the drugs used and the gestational age of the fetus. During the period of organogenesis (4 to 13 wk), administration of cytotoxic drugs carries an increased risk of fetal malformations and fetal loss. Chemotherapy in the second or third trimester is associated with intrauterine growth retardation, prematurity, and low birth weight and bone marrow toxicity in many exposed infants.

Author Information

*Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, Connecticut

Herbert Wertheim College of Medicine, Florida International University, Miami , Florida

The authors declare that they have nothing to disclose.

Correspondence: Molly A. Brewer, DVM, MD, MS, Division of Gynecologic Oncology, Carole and Ray Neag Comprehensive Cancer Center University of Connecticut Health Center, 263 Farmington Ave MC 1614, Farmington, CT 06030-2875. E-mail: mbrewer@uchc.edu.

© 2011 Lippincott Williams & Wilkins, Inc.